Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AQP1 | P29972 | 1/20 | 0.70 |
| ▸ | CA2 | P00918 | 2/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.67 |
| ▸ | USP2 | O75604 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | HPGD | P15428 | 1/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | BLM | P54132 | 1/20 | 0.67 |
| ▸ | SLC12A2 | P55011 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | PTGS2 | P35354 | 14/20 | 0.59 |
| ▸ | MMP13 | P45452 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12508001 | 1.00 | AQP1 (0.70) | AQP1CA2KDM4EUSP2ALDH1A1 | |
| SCHEMBL10224186 | 0.92 | CA2 (0.77) | AQP1CA2KDM4EUSP2ALDH1A1 | |
| SCHEMBL12508357 | 0.91 | AQP1 (0.78) | AQP1CA2KDM4EUSP2ALDH1A1 | |
| SCHEMBL12508288 | 0.85 | HPGD (0.69) | AQP1CA2KDM4EUSP2ALDH1A1 | |
| SCHEMBL18993682 | 0.85 | AQP1 (0.49) | AQP1CA2KDM4EUSP2ALDH1A1 | |
| SCHEMBL11374781 | 0.83 | CA2 (0.84) | AQP1CA2KDM4EUSP2ALDH1A1 | |
| SCHEMBL31704475 | 0.83 | CA2 (0.84) | AQP1CA2KDM4EUSP2ALDH1A1 | |
| SCHEMBL2742069 | 0.82 | KDM4E (0.86) | AQP1CA2KDM4EUSP2ALDH1A1 | |
| SCHEMBL12508360 | 0.82 | AQP1 (1.00) | AQP1CA2KDM4EUSP2ALDH1A1 | |
| SCHEMBL10224121 | 0.82 | CA2 (0.72) | AQP1CA2KDM4EUSP2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119303086-A | Pharmaceutical composition for treating autism | 斯塔利克拉股份有限公司 | 2025-01-14 | — | — | CN | claimed |
| EP-3498297-B1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | STALICLA S A (CH) | 2023-06-21 | — | — | EP | claimed |
| US-20230134747-A1 | COMPOSITIONS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER | STALICLA SA (CH) | 2023-05-04 | — | — | US | claimed |
| CN-115811974-A | Compositions for treating autism spectrum disorders | 斯塔利克拉股份有限公司 | 2023-03-17 | — | — | CN | claimed |
| EP-4121034-A1 | COMPOSITIONS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER | Stalicla S.A. (CH) | 2023-01-25 | — | — | EP | claimed |
| US-11439627-B2 | Pharmaceutical composition for the treatment of autism | Stalicla S.A. (CH) | 2022-09-13 | — | — | US | claimed |
| US-20250339410-A1 | TREATMENT FOR AUTISM SPECTRUM DISORDER | STALICLA SA (CH) | 2025-11-06 | — | — | US | disclosed |
| US-20250295641-A1 | TREATMENT FOR ASD | STALICLA SA (CH) | 2025-09-25 | — | — | US | disclosed |
| CN-119303086-A | Pharmaceutical composition for treating autism | 斯塔利克拉股份有限公司 | 2025-01-14 | — | — | CN | disclosed |
| EP-3498297-B1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | STALICLA S A (CH) | 2023-06-21 | — | — | EP | disclosed |
| US-20230134747-A1 | COMPOSITIONS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER | STALICLA SA (CH) | 2023-05-04 | — | — | US | disclosed |
| CN-115811974-A | Compositions for treating autism spectrum disorders | 斯塔利克拉股份有限公司 | 2023-03-17 | — | — | CN | disclosed |
| EP-4121034-A1 | COMPOSITIONS FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER | Stalicla S.A. (CH) | 2023-01-25 | — | — | EP | disclosed |
| US-11439627-B2 | Pharmaceutical composition for the treatment of autism | Stalicla S.A. (CH) | 2022-09-13 | — | — | US | disclosed |
| US-20220280490-A1 | TREATMENT OF FRAGILE X SYNDROME | HEALX LTD (GB) | 2022-09-08 | — | — | US | disclosed |
| EP-4013409-A1 | TREATMENT OF FRAGILE X SYNDROME | Healx Limited (GB) | 2022-06-22 | — | — | EP | disclosed |
| EP-3984555-A1 | PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF AUTISM | Stalicla S.A. (CH) | 2022-04-20 | — | — | EP | disclosed |
| CN-114302723-A | Treatment of fragile X syndrome | HEALX有限公司 | 2022-04-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250339410-A1 | TREATMENT FOR AUTISM SPECTRUM DISORDER | GABRQ, GABRB1, GABRB3 | AQP1 3888/4885CA2 1771/4885KDM4E 892/4885 |
| US-20250295641-A1 | TREATMENT FOR ASD | NFKBIA, RELA, IKBKB | AQP1 4081/4885CA2 3035/4885KDM4E 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.